ArticleBMJ open2026
Impact of fertility preservation on quality of life, recurrence and reproductive success in young female cancer survivors: a Korean prospective multicentre cohort study protocol (LIFE-Repro).
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGynaecological cancers increasingly affect women of reproductive age, necessitating fertility-sparing treatments that balance oncological safety with reproductive potential. However, the long-term impact of these treatments on survivorship-specifically regarding sexual function, quality of life (QoL) and reproductive outcomes-remains understudied. LIFE-Repro is a prospective multicentre cohort study designed to evaluate these impacts in young female cancer survivors. METHODS AND ANALYSIS: Between 2023 and 2027, eleven tertiary referral hospitals in Korea will recruit 200 patients aged ≤45 years with gynaecological cancers who have undergone fertility-sparing treatment. Participants will undergo baseline assessments followed by prospective follow-ups every 6 months. At each visit, patient-reported outcomes assessing sexual function, QoL and health status will be collected using a mobile application developed by the research team. The primary endpoint is the incidence of post-treatment sexual dysfunction measured by the Female Sexual Function Index-Korean version. Secondary endpoints include longitudinal changes in QoL, cancer recurrence, survival, pregnancy rates, live birth rates and premature menopause. ETHICS AND DISSEMINATION: The study protocol was approved by the Institutional Review Board of Korea University Guro Hospital (2024GR0484). Results will be disseminated through peer-reviewed journals and conference presentations. TRIAL REGISTRATION NUMBER: KCT0009578.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.